Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

NCT ID: NCT06110208

Last Updated: 2025-02-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-10
• Study Completion Date: 2024-07-01

Brief Summary

This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population were patients with relapsed and refractory acute myeloid leukemia (r/r AML) .

Detailed Description

Single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population was patients with relapsed and refractory acute myeloid leukemia (r/r AML) .

Conditions

Acute Myeloid Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AML subjects

This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population was patients with relapsed and refractory acute myeloid leukemia (r/r AML) .

Group Type: EXPERIMENTAL

CLL1 and CD38 dual-target CAR-T injection

Intervention Type: DRUG

CLL1 and CD38 dual-target CAR-T injection

Interventions

CLL1 and CD38 dual-target CAR-T injection

CLL1 and CD38 dual-target CAR-T injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 18-70 years old (including the critical value) when signing the informed consent form;

2. Diagnosed with acute myeloid leukemia (excluding APL) according to the World Health Organization 2016 criteria and relapsed and refractory AML according to the ELN2022 criteria;

3. Positive expression of CLL1 and/or CD38 in malignant cells must be detected by immunohistochemistry or flow cytometry (≥20 % );

4. If there are AEs caused by previous chemotherapy, it must be restored to CTCAE V5.0 grade 1;

5. Estimated survival time ≥3 months;

6. ECOG score 0 or 1 during screening period;

7. Hemoglobin ≥80g/L (have not received red blood cell transfusion within 7 days before screening, use of recombinant human erythropoietin is allowed);

8. Adequate organ functional reserve:

1. Alanine aminotransferase/aspartate aminotransferase ≤2.5× ULN (upper limit of normal value);

2. Serum total bilirubin ≤2× ULN, except for subjects with congenital bilirubinemia (for subjects with Gilbert syndrome, direct bilirubin needs to be ≤1.5× ULN);

3. Serum creatinine clearance >45mL/min (calculated according to the Cockcroft-Gault formula);

4. Left ventricular ejection fraction ≥35%;

5. Basic oxygen saturation in indoor air environment is ≥ 92 %

9. Ability to discontinue corticosteroids (dexamethasone ≥3 mg/day or other equivalent doses of steroids) starting on day -7 and continuing until 30 days after CAR-T cell infusion;

10. Women of childbearing age must have a negative pregnancy test for human chorionic gonadotropin (HCG) (immunofluorescence method) during the screening period and baseline period. Male subjects will need to agree not to donate sperm for at least one year after reinfusion. Males and sexual partners of childbearing potential agree to use highly effective contraceptive measures for at least 1 year after infusion;

11. Agree to perform follow-ups in accordance with the requirements of the protocol and informed consent form;

12. With the consent of the subject and the informed consent form voluntarily signed by the subject or his legal representative.

Exclusion Criteria

1. Diagnosis of acute promyelocytic leukemia;

2. clinical trial investigational drugs or cell therapies within 2 weeks or 5 half-lives ;

3. Acute myeloid leukemia of unknown lineage ;

4. Those who have active graft-versus-host disease (GVHD) at the time of enrollment or develop active acute or chronic GVHD within 4 weeks after enrollment or require immunosuppressive drugs to treat GVHD;

5. There is an active infection;

6. Suffering from other malignant tumors (except non-melanoma skin cancer and in situ cervical cancer, bladder cancer, and breast cancer with a disease-free survival period of more than 5 years);

7. The subject has had a stroke or epilepsy within 6 months before signing the informed consent form;

8. The subjects' cardiac function showed the following conditions:

1. New York Heart Association (NYHA) class III or IV heart failure;

2. Myocardial infarction or coronary artery bypass grafting (CABG) occurred within 6 months before signing the informed consent form;

3. A history of clinically significant ventricular arrhythmia or syncope of unknown origin (not caused by vasovagal or dehydration);

4. Have a history of severe non-ischemic cardiomyopathy;

5. Cardiac dysfunction (left ventricular <35%) assessed by echocardiography or multiple gated acquisition scans, or other heart disease with clinical symptoms within 6 months before enrollment;

9. Active or previous central nervous system involvement, or clinically significant clinical manifestations of central nervous system involvement in subjects with acute myeloid leukemia ;

10. A positive virological test result for any of the following:

1. Human immunodeficiency virus antibodies (HIV antibodies);

2. Hepatitis C virus antibody (HCV antibody), those who are positive need to be tested for HCV-RNA, and those whose values are lower than the lower limit of the detection value can be enrolled;

3. HBsAg positive; or HBcAb positive; if HBcAb is positive, further testing of HBV DNA copy number is required . Those who are lower than the lower limit of the detection value can be enrolled;

4. Treponema pallidum antibodies (TPPA antibodies);

11. presence of pulmonary fibrosis;

12. Severe allergic history or allergic constitution;

13. The subject has undergone open injury or major surgery (referring to level III surgery and level IV surgery) within 2 weeks before signing the informed consent form, or plans to have surgery during the trial or within 2 weeks after reinfusion (excluding local anesthesia surgery) ;

14. for cyclophosphamide combined with fludarabine ;

15. Cannulae or drains other than central venous catheters;

16. Pregnant women, lactating women, or men who plan to give birth within 1 year of receiving treatment;

17. Any other circumstances that the researcher deems inappropriate for inclusion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gracell Biotechnologies (Shanghai) Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sanbin Wang

Role: PRINCIPAL_INVESTIGATOR

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Locations

920th Hospital of Joint LogisticsSupport Force of People's Liberation

Kunming, Yunnan, China

Countries

China

Other Identifiers

GC12-132

Identifier Type: -

Identifier Source: org_study_id